<DOC>
	<DOCNO>NCT00051688</DOCNO>
	<brief_summary>The primary purpose study determine best dose tezacitabine combine oxaliplatin patient metastatic colorectal cancer . This study also evaluate tumor response combination anti-cancer drug .</brief_summary>
	<brief_title>Tezacitabine Oxaliplatin Treatment Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Tezacitabine</mesh_term>
	<criteria>Patients metastatic colorectal adenocarcinoma fail one prior course chemotherapy . Patients must least one measurable tumor . Patients may receive prior treatment oxaliplatin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>